Nano-scale molecular profiling, screening and discovery
NanoMosaic is a Boston-area biotechnology company developing a next-generation protein interrogation platform powered by proprietary nanoneedle technology licensed from Harvard University. The company's MosaicNeedles™ platform enables high-throughput, ultrasensitive detection and quantification of proteins, nucleic acids, and other analytes on a single chip, supporting early disease detection, prognostic monitoring, and biomarker discovery. NanoMosaic's tools are designed for researchers in oncology, neurology, and gene therapy, offering a workflow that integrates seamlessly with existing laboratory processes. The platform has been applied to developing clinical biomarker tests for conditions including cancer and neurological diseases.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2021
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
